ovo like zinc finger 2Genealiases: CHED · CHED1 · CHED2 · EUROIMAGE566589 · PPCD1 · ZNF339
Q-omics provides the consensus-scored OVOL2 profile across patient tissues and cancer cell-line models. OVOL2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OVOL2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, OVOL2 RNA expression shows 16,378 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where OVOL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OVOL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OVOL2 survival associations across molecular data types. OVOL2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OVOL2 RNA expression–survival associations across cancer types. High OVOL2 expression shows unfavorable associations in ACC, SKCM and LIHC, but favorable associations in UCEC, BRCA and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ACC as the clearest survival context for OVOL2 RNA expression.
This table summarizes OVOL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for OVOL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OVOL2 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in BLCA, UCEC and BRCA. The KIRC box plot shows higher OVOL2 RNA expression in normal versus tumor tissue (log2 FC = −1.958, t-test p < 0.001).
This table shows molecular features associated with OVOL2 in patient tissues and cancer cell lines. In patient samples, OVOL2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, OVOL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
